AllianceBernstein’s Black Diamond Therapeutics BDTX Stock Holding History

AllianceBernstein’s Portfolio BDTX Stock Details BDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$68.9K	Buy	+32,340	New	+$79.1K	﹤0.01%	3281
2025 Q2	–	Sell	-21,640	Closed	-$33.5K	–	3242
2025 Q1	$33.5K	Hold	21,640	–	–	﹤0.01%	3161
2024 Q4	$46.3K	Hold	21,640	–	–	﹤0.01%	3189
2024 Q3	$94.1K	Buy	21,640 +4,300	+25%	+$23.4K	﹤0.01%	3139
2024 Q2	$80.8K	Buy	+17,340	New	+$93.1K	﹤0.01%	3142
2022 Q2	–	Sell	-34,600	Closed	-$96K	–	3274
2022 Q1	$96K	Buy	34,600 +100	+0.3%	+$365	﹤0.01%	3117
2021 Q4	$184K	Hold	34,500	–	–	﹤0.01%	3093
2021 Q3	$292K	Hold	34,500	–	–	﹤0.01%	2959
2021 Q2	$421K	Buy	34,500 +19,600	+132%	+$387K	﹤0.01%	2885
2021 Q1	$361K	Hold	14,900	–	–	﹤0.01%	2826
2020 Q4	$478K	Buy	14,900 +600	+4%	+$19.7K	﹤0.01%	2617
2020 Q3	$432K	Sell	14,300 -800	-5%	-$24.3K	﹤0.01%	2597
2020 Q2	$637K	Buy	15,100 +6,200	+70%	+$228K	﹤0.01%	2454
2020 Q1	$222K	Buy	+8,900	New	+$271K	﹤0.01%	2756

Other funds holding BDTX

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

DCM

Defilade Capital Management Emeryville, California $747M AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

AllianceBernstein's BDTX Position: Q2 2026 in Review

AllianceBernstein opened a new position in Black Diamond Therapeutics (BDTX) in Q2 2026: 32,340 shares worth $68.9K. The stake represents ﹤0.01% of the portfolio and ranks #3281 among its holdings. This is a return to the name: AllianceBernstein previously reported a position in BDTX as recently as Q1 2025.

AllianceBernstein first reported a position in BDTX in Q1 2020 and has held it in 14 quarters since. The position peaked at $637K in Q2 2020. 96 funds tracked by Wall St. Rank hold BDTX as of Q2 2026.

AllianceBernstein held 32,340 shares of Black Diamond Therapeutics worth $68.9K as of Q2 2026.
Black Diamond Therapeutics was a new AllianceBernstein position in Q2 2026.
Black Diamond Therapeutics made up ﹤0.01% of AllianceBernstein's portfolio in Q2 2026, its #3281 holding.
AllianceBernstein first reported a position in Black Diamond Therapeutics in Q1 2020 and has held it in 14 quarters since.
AllianceBernstein's Black Diamond Therapeutics position peaked at $637K in Q2 2020.
96 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q2 2026.

Based on AllianceBernstein's 13F filing for Q2 2026, filed 14 Aug 2026.